ERT, a provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, was awarded three new contracts with pharmaceutical companies, totalling over $10 million for its electronic patient reported outcomes (ePRO) business.

The first ePRO award is an agreement with a specialty division of a pharmaceutical company that has selected ERT to manage a suite of studies using ERT’s proprietary VIAPhone platform over the next three years.  The contract will be worth in excess of $7 million. The second award is part of a $3.0 million contract for which ERT will provide its VIAPen solution for a pivotal phase III program. The third award has been secured with a pharmaceutical company that will be using ERT’s VIAPhone Pain Diary for use in a phase III clinical trial, alongside its VIAPen solution for site assessments.

John Blakeley, chief commercial officer at ERT, comments: “The broad scope of our solutions and expertise ensures that we are able to offer clients unbiased, ‘true partnership’ advice that allows for an accurate and cost-effective trial. Sponsors are increasingly choosing ERT for our industry knowledge and expertise as well as secure and reliable service.”